Max Healthcare inks pact for genomics research with Anuva

Max Healthcare inks pact for genomics research with Anuva

The pact involves Max Healthcare providing its expertise in clinical research along with a base for data and sample collection.

FPJ Web DeskUpdated: Tuesday, December 27, 2022, 10:13 PM IST
article-image

Max Healthcare and genomics biotech firm Anuva have joined forces to for genomic-based research focusing on communicable and non-communicable diseases in India, through an MoU. To be conducted over the next five years, the research will seek insights on application of precision medicine for breast cancer, lung cancer, diabetes, cardiac disease, kidney disease, and drug resistant tuberculosis, among others.

The pact involves Max Healthcare providing its expertise in clinical research along with a base for data and sample collection

Anuva provides translational research for a diverse genomic bio and data bank that will cater to Asian populations. The agreement also involves working on the possibility of conducting joint training, fellowships, exchange visits, knowledge and technology transfer.

RECENT STORIES

New Wage Code Comes Into Force, Expands Coverage & Strengthens Worker Protection; Aims To Boost...

New Wage Code Comes Into Force, Expands Coverage & Strengthens Worker Protection; Aims To Boost...

AdaniConneX Acquires Trade Castle Tech Park For ₹231 Crore To Boost Infrastructure Plans

AdaniConneX Acquires Trade Castle Tech Park For ₹231 Crore To Boost Infrastructure Plans

Seven Of India’s Top-10 Firms Add ₹1.28 Lakh Crore In Market Value, RIL & Airtel Lead Weekly...

Seven Of India’s Top-10 Firms Add ₹1.28 Lakh Crore In Market Value, RIL & Airtel Lead Weekly...

Tata Motors Expects Double-Digit Growth In Second Half With Pent-Up Demand Boosting PV Volumes

Tata Motors Expects Double-Digit Growth In Second Half With Pent-Up Demand Boosting PV Volumes

Q2 GDP Data & Global Cues To Steer Markets This Week, Investors Expected To Stay Selective Amid...

Q2 GDP Data & Global Cues To Steer Markets This Week, Investors Expected To Stay Selective Amid...